News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly ODYSSEY insights: race and ethnicity, very high-risk patients Inclisiran: The Phase 3 trial FOURIER trial: Update on subgroup analyses ODYSSEY OUTCOMES: Update ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Download Now: New Slide Deck Programme

Slide decks focusing on key results and expert analysis from FOURIER and ODYSSEY OUTCOMES – two landmark trials in PCSK9 inhibition.

Find out more »

Download NowUNIQUE FREE APPAdvances in lipid lowering - a clinical guide

News from the 87th European Atherosclerosis Society Congress

News from ORION-2, ORION-3 with inclisiran

Novel PCSK9 adnectin LIB003 looks good

Screening for FH helps prevent early death

ACC Scientific Sessions 2019

What was the PCSK9 news at this year’s Congress?

ODYSSEY OUTCOMES: Lipoprotein(a) analysis

More insights from ODYSSEY OUTCOMES

Most viewed

VIDEO: AHA/ACC 2018 Cholesterol Guidelines also have good points Will CANTOS and REVEAL change how we view the clinical use of PCSK9 inhibitors? Legacy effects: Does early intensive LDL lowering treatment modify the atherosclerotic process? Prof Henry Ginsberg discusses the ODYSSEY Outcomes topline data Professor Raul Santos (University of São Paulo, Brazil): Why was the mortality benefit in ODYSSEY Outcomes only evident after 1 year of follow-up? LDL cholesterol goals in patients with diabetes – How low? Does PCSK9 inhibition on top of statin therapy offer the possibility of further reducing plaque burden? ORION-1 Prof John Chapman discusses safety data from the ODYSSEY Outcomes study Preventing cardiovascular disease: the value of early signs of cardiac injury

Most viewed

VIDEO: AHA/ACC 2018 Cholesterol Guidelines also have good points

Hot Topics

News from the 10th Expert Meeting of the Editorial Board of PCSK9 Education and Research Forum

Treatment Guidelines: Now and the Future

Professor Henry Ginsberg (University of Columbia, New York, USA): The 2018 AHA/ACC Treatment Guidelines: Key learnings

Watch Webcast

Professor Børge Nordestgaard (University of Copenhagen, Denmark): Lipoprotein(a): a therapeutic target in guidelines?

Watch Webcast

From the Editors

LDL cholesterol goals in patients with diabetes – How low?

Professor Derick Raal, University of the Witwatersrand, Johannesburg, South Africa

Do we need to treat LDL cholesterol more aggressively in diabetes patients, especially those with a history of ACS? A new analysis from ODYSSEY OUTCOMES lends support to this approach.

Read the report